Melissa Ramocki
Neurology · E Greenwich, RINPI 1821255035
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,613 of the $2,744 with a category attached, or 95.2%. Ionis Pharmaceuticals, Inc. accounts for 95.2% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $2,613, more than ten times the $95 reported in 2019.
Across 10 payments — averaging $274.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ionis Pharmaceuticals, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$42
- Amgen$30
- Biohaven Pharmaceutical Holding Company Ltd.$24
- Supernus Pharmaceuticals, Inc.$23
- Impel Pharmaceuticals Inc.$12
What the payments were for
- Consulting fees$2,61395%
- Food & beverage$1204%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ionis Pharmaceuticals, Inc. | 1 | $2,613 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| Amgen | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 2 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$2,744 in reported general payments places this provider in the 65th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 16 | $29,673 |
| Emgality PenGalcanezumab-Gnlm | 12 | $10,898 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $1,148 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 58 | $1,114 |
| RizatriptanRizatriptan Benzoate | 33 | $443 |
| Ondansetron Hcl | 38 | $231 |
| Escitalopram Oxalate | 15 | $175 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 22 | $139 |
| Ondansetron OdtOndansetron | 15 | $103 |
| Lorazepam | 13 | $11 |
Paid to pharmacies, not to this prescriber.
Other neurology in E Greenwich
- Stephen SallowayProvidence$329K
- Peter BellafioreWakefield$274K
- Norman GordonEast Providence$206K
- Syed RizviProvidence$160K
- Albert MaranoJohnston$145K
- John EastonProvidence$112K
- Roderick SpearsSmithfield$92K
- Saima ChaudhryProvidence$90K
- Dennis AumentadoNorth Smithfield$70K
- Monica DhakarProvidence$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.